Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

9.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Cancer Vaccines01:30

Cancer Vaccines

574
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
574
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Two-Year Outcomes After Direct-to-Surgery in Good Prognosis Margin-Clear Stage II or III Rectal Cancer-The QuickSilver Study.

Annals of surgical oncology·2026
Same author

Two-Year Outcomes after Direct-to-Surgery in Good Prognosis Margin-Clear Stage II or III Rectal Cancer: The QuickSilver Study.

Annals of surgical oncology·2026
Same author

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

NEJM evidence·2026
Same author

Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases-A Multicenter Canadian Study.

Current oncology (Toronto, Ont.)·2026
Same author

Pre-operative positron emission tomography scan is associated with lower rates of adjuvant treatment in surgically treated patients with cervical cancer: a 4C Working Group study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

A Randomized Trial Evaluating Personalized Versus Guideline-Based Well Follow-Up Strategies for Patients with Early Breast Cancer: Feasibility Outcomes.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Oct 22, 2025

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.0K

Advancing Academic Cancer Clinical Trials Recruitment in Canada.

Rebecca Y Xu1, Diana Kato1, Gregory R Pond2

  • 1Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada.

Current Oncology (Toronto, Ont.)
|August 26, 2021
PubMed
Summary

The Canadian Cancer Clinical Trials Network (3CTN) successfully boosted academic cancer clinical trials (ACCT) recruitment by 59.6% within four years. This initiative met its goals, enhancing patient access to vital cancer research and improving outcomes.

Keywords:
Canadian cancer clinical trialsacademic cancer trialsfundingpatient recruitment

More Related Videos

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
09:23

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation

Published on: August 18, 2016

10.6K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.3K

Related Experiment Videos

Last Updated: Oct 22, 2025

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.0K
Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
09:23

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation

Published on: August 18, 2016

10.6K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.3K

Area of Science:

  • Oncology
  • Clinical Research
  • Health Services Research

Background:

  • Academic cancer clinical trials (ACCT) activity faced a decline.
  • The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address this issue.
  • Funding models were implemented to support ACCTs across Canadian cancer centers.

Purpose of the Study:

  • To evaluate the effectiveness of the 3CTN in increasing ACCT activity.
  • To identify factors predicting successful patient recruitment in ACCTs.
  • To assess the impact of the 3CTN on cancer trial access and patient outcomes.

Main Methods:

  • A portfolio approach to funding cancer centers for ACCTs.
  • Implementation of core and incentive-based funding structures.
  • Tracking of established performance measures, including patient recruitment.
  • Statistical analysis to identify success factors for recruitment targets.

Main Results:

  • From 2014-2018, 11,275 patients were recruited to 559 trials.
  • Overall recruitment increased by 59.6% above the pre-3CTN baseline by Year 4.
  • The overall recruitment target was achieved within three years, with 51% of adult centers meeting the Year 4 target.
  • Time period, region, and number of baseline trials were identified as key factors for achieving recruitment targets.

Conclusions:

  • The 3CTN successfully met its objectives for increasing ACCT activity.
  • The network demonstrated a significant positive impact on patient recruitment and trial access.
  • Continued support and funding are recommended to sustain and enhance ACCTs for improved patient outcomes.